Fast Five Quiz: Severe Pediatric Atopic Dermatitis

William D. James, MD

Disclosures

March 15, 2021

Topical vitamin D analogs are not approved for use in pediatric patients.

The FDA has approved dupilumab, a targeted biologic, for use in children 6-11 years of age with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are inappropriate.

Crisaborole, a PDE-4 inhibitor, is approved by the FDA for use in infants and children 3 months or older.

Topical administration of the calcineurin inhibitor pimecrolimus is approved as a second-line therapy for the short-term treatment of atopic dermatitis in children 2 years and older who are not immunocompromised, whose disease is not adequately controlled with topical prescription therapies, or when those therapies are inappropriate.

Learn more about medication in atopic dermatitis.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....